论文部分内容阅读
Drug-eluting stent (DES) has markedly reducedrestenosis and the need for target lesionrevascularization (TLR). The safety profile of DES doesnot seem to differ from that of bare metal stent in theacute and subacute phases following coronaryintervention. However, at World Congress of Cardiology2006 a meta-analysis of randomized trials suggested that
The safety profile of DES does not seem to differ from that of bare metal stent in theacute and subacute phases following coronary intervention. However, at World Congress of Cardiology 2006 a meta-analysis of randomized trials suggested that